Key terms

About ELAN

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ELAN news

Yesterday 5:54pm ET Elanco Animal Health Stock (NYSE:ELAN): Hurdles Remain Despite Hitting 52-Week High Yesterday 8:20am ET Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN) Yesterday 5:31am ET Analysts’ Top Healthcare Picks: Elanco Animal Health (ELAN), Syndax Pharmaceuticals (SNDX) Yesterday 5:19am ET Elanco price target raised to $23 from $19 at Barclays May 08 12:00pm ET Elanco rises 24.7% May 08 10:00am ET Elanco rises 21.6% May 08 6:37am ET Elanco reports Q1 adjusted EPS 34c, consensus 26c May 07 8:25pm ET Notable companies reporting before tomorrow’s open May 07 1:55pm ET Notable companies reporting before tomorrow’s open May 07 7:43am ET Barclays Keeps Their Buy Rating on Elanco Animal Health (ELAN) Apr 22 12:30pm ET Jefferies cuts Zoetis target, says vet survey positive for Librela Apr 01 8:43am ET Elanco Enhances Board Governance with Strategic Appointments Mar 12 6:47am ET Elanco price target raised to $18 from $12 at Piper Sandler Mar 12 6:36am ET Elanco Animal Health (ELAN) Gets a Hold from Piper Sandler Mar 05 9:40am ET Unusually active option classes on open March 5th Mar 04 8:38am ET Elanco appoints Shiv O’Neill as General Counsel and Corporate Secretary Feb 29 1:13pm ET Elanco responds to Ancora board nominations Feb 29 8:17am ET Ancora nominates four director candidates, urges CEO succession at Elanco Feb 27 7:44am ET Stifel Nicolaus Sticks to Its Buy Rating for Elanco Animal Health (ELAN) Feb 27 5:51am ET Buy Rating Affirmed on Elanco Animal Health Amid Solid FY2024 Guidance and Business Stabilization Feb 27 5:33am ET Elanco price target raised to $19 from $18 at Barclays Feb 27 3:30am ET Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Elanco Animal Health (ELAN) and R1 RCM (RCM) Feb 27 1:00am ET Elanco Animal Health’s New Share Price & Shareholder Rights Risk – A Cause for Worry? Feb 26 8:16am ET ELAN Earnings: Elanco Ticks Lower on Mixed Q4 Performance Feb 26 6:31am ET Elanco sees Q1 EPS 25c-28c, consensus 30c Feb 26 6:30am ET Elanco sees FY24 adjusted EPS 87c-95c, consensus 89c Feb 26 6:28am ET Elanco reports Q4 adjusted EPS 8c, consensus 11c Feb 22 5:08am ET Barclays Sticks to Its Buy Rating for Elanco Animal Health (ELAN)

ELAN Financials

1-year income & revenue

Key terms

ELAN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ELAN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms